Zymeworks Inc. (NYSE: ZYME) was founded in 2003 and is headquartered in Vancouver, Canada, with 145 full-time employees. It is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of biological therapies for cancer treatment in Canada.
Zymeworks Inc. (ZYME):
Zymeworks is a publicly listed biotechnology company located in Vancouver, British Columbia. It develops protein therapies for the treatment of cancer and autoimmune and inflammatory diseases. The products are developed based on the company’s molecular modeling software for optimizing protein structure.
According to PitchBook data, Zymeworks raised $44 million in funding in 2014, ranking among the top 10 global health technology (HealthTech) companies that raised funds that year.
In May 2017, Zymeworks held an initial public offering on the Toronto Stock Exchange, raising $59 million. This is Canada’s largest biotech IPO in more than a decade. In alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focusing on the treatment of cancer. Zymeworks’ complementary treatment platform suite and fully integrated drug development engine provide flexibility and compatibility to accurately design and develop highly differentiated product candidates.
Zymeworks’ lead product candidate, ZW25, is a new bispecific antibody that is currently being evaluated in an adaptive phase I clinical trial. Zymeworks is also advancing the in-depth development of preclinical product candidates and discovery stage products in immuno-oncology and other therapeutic fields.
In addition to Zymeworks’ wholly-owned product line, its therapeutic platform has also been further developed through multiple strategic partnerships with global biopharmaceutical companies, including: Merck Sharp & Dohme Research Ltd. (Mersha Dong); Eli Lilly and Company ( Eli Lilly); of Celgene Corporation and the Investment of Celgene Alpine Co. LLC. (pharmaceuticals new group); GlaxoSmithKline Intellectual Property Development Limited (GSK); of Daiichi Sankyo Co., Ltd.’s ( Daiichi Sankyo ) and Janssen Biotech , Inc ..